medullary thyroid cancer | Ricerc@Sapienza

Oncological Endocrinology

Working in the largest University Hospital in central Italy, we are a referral center for oncological patients suffering from a variety of tumors and/or developing endocrine complications. This comprises a lot of clinical work that gives us the opportunity to improve their quality of life, morbidity and mortality. We strive to give the most to our patients, and they give back energy, motivation and their happy participation in several clinical studies.

Informazioni

Struttura
Spin OFF
KET
Keywords
Progetti principali
Altre informazioni

Componenti del gruppo

Nome	E-mail

Collaboratori nazionali ed internazionali

Laboratori

Pubblicazioni

Brevetti

Progetti di ricerca

ERC

ERC	Descrizione

Infrastrutture

Leggi tutto su Oncological Endocrinology

Sunitinib in the treatment of thyroid cancer

Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors.

Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma

Aim: Due to the limits of calcitonin, other markers are warranted to better manage medullary thyroid carcinoma
patients, and procalcitonin has been reported as promising. Here we aimed to evaluate procalcitonin as a marker
of medullary thyroid carcinoma in the post-treatment follow-up.
Methods: Medullary thyroid carcinoma patients previously treated by thyroidectomy were enrolled. After complete
imaging work-up (i.e. ultrasonography, computed tomography, magnetic resonance and 18FDG-PET-CT) we

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study

Purpose Medullary thyroid cancer (MTC) is a neuroendocrine tumour of the thyroid C cells. Pasireotide, a multi-receptor targeted somatostatin analogue, and everolimus, an inhibitor of mTOR, showed antitumour properties in neuroendocrine tumours. Aim of this study was to evaluate pasireotide alone and in combination with everolimus in patients with MTC.